Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

This study is testing whether adding a drug called chidamide to the standard R-CHOP chemotherapy regimen can improve outcomes for people newly diagnosed with a specific form of aggressive lymphoma called Double-Expressor Diffuse Large B-Cell Lymphoma, classified as the 'Other' molecular subtype. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with Diffuse Large B-Cell Lymphoma confirmed by biopsy - Your tumor has been classified as the 'Other' molecular subtype by genetic testing - Your tumor over-expresses certain proteins (MYC and BCL2) on testing - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have previously received treatment for this lymphoma - You have significant heart, liver, kidney, or other organ problems - You do not meet the required blood count and lab values Talk to your doctor to see if this trial is right for you.